Global Postpartum Hemorrhage (PPH) Treatment Devices Market to Reach US$1.1 Billion by 2030

The global market for Postpartum Hemorrhage (PPH) Treatment Devices estimated at US$851.9 Million in the year 2024, is expected to reach US$1.1 Billion by 2030, growing at a CAGR of 4.6% over the analysis period 2024-2030. Uterine Balloon Tamponade, one of the segments analyzed in the report, is expected to record a 4.3% CAGR and reach US$521.7 Million by the end of the analysis period. Growth in the Non-Pneumatic Anti-Shock Garment (NASG) segment is estimated at 4.6% CAGR over the analysis period.

The U.S. Market is Estimated at US$289.6 Million While China is Forecast to Grow at 6.1% CAGR

The Postpartum Hemorrhage (PPH) Treatment Devices market in the U.S. is estimated at US$289.6 Million in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$146.8 Million by the year 2030 trailing a CAGR of 6.1% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.2% and 4.6% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.7% CAGR.

Global Postpartum Hemorrhage (PPH) Treatment Devices Market - Key Trends & Drivers Summarized

Postpartum hemorrhage (PPH), also termed as postpartum bleeding, is a medical complication characterized by loss of over 500ml or 1,000ml of blood in women within the initial 24 hours after childbirth. Prevalent across both developed and developing countries, the condition is linked with a large number of mortalities. Uterine massage is considered as the first line treatment for ensuring contraction of the uterus and reducing bleeding. On the other hand, various medical professionals rely on non-pneumatic anti-shock garment (NASG) for delivery outside a healthcare setting. The approach improves shock in the pregnant women with obstetrical bleeding, providing the rime to reach hospital. Uterine balloon tamponades are also used for treating PPH among patients who are unresponsive to primary interventions and uterotonics. Uterine balloon tamponade hold potential to considerable improve the condition. In addition, inflating the Sengstaken–Blakemore tube in uterus can treat atonic PPH in majority of cases.

Technological advancements have led to the development of more effective and user-friendly devices, which are being increasingly adopted in both developed and developing countries. Uterine balloon tamponades, such as the Bakri balloon, have become standard in many medical settings due to their effectiveness and ease of use. These devices can be rapidly deployed and are minimally invasive, making them suitable for use in diverse healthcare environments, including low-resource settings. Electrosurgical devices and hemostatic agents have also evolved, offering precise and effective means to control bleeding. Non-pneumatic anti-shock garments, which apply circumferential pressure to reduce blood loss and maintain vital organ perfusion, are increasingly used in emergency settings, particularly in developing countries. The integration of these devices with digital monitoring systems allows for real-time assessment and management of blood loss, improving patient outcomes.

The growth in the PPH treatment devices market is driven by several factors, including rising global incidence of PPH and the growing awareness about maternal health. Rising complications concerning pregnancy, namely large-sized babies, multiple pregnancies, and inverted uterus are also fueling market growth. Further, increase in other risk factors of PPH, like traumatic uterine and uterine atony, an increase in pregnant women with anemia conditions, and rising awareness concerning PPH risks boost the market growth of postpartum hemorrhage devices. The expanding healthcare infrastructure, especially in emerging economies, has facilitated greater access to these advanced treatment options. Moreover, government initiatives and funding aimed at reducing maternal mortality rates have bolstered market growth. The demand for minimally invasive and easy-to-use devices that can be employed in a variety of healthcare settings, from tertiary care hospitals to rural clinics, has also spurred innovation in this field. These factors collectively ensure the robust expansion of the market, addressing a critical need in maternal healthcare.